Could childhood bacteria be driving colon cancer in millennials?
Childhood exposure to a bacterial toxin in the colon may be triggering the increase in colorectal cancer cases among younger patients, a new study suggests.Once considered a disease of older adults, colorectal cancer is now on the rise among young people in at least 27 countries. Its incidence in adults under 50 has roughly doubled every decade for the past 20 years.advertisementLooking for clues as to why, the researchers analyzed genes of 981 colorectal cancer tumors from patients with varying colorectal cancer risk levels who had early- or late-onset disease in 11 countries.
DNA mutations in colon cells that are known to be caused by a toxin produced by Escherichia coli, called colibactin, were 3.3 times more common in adults who developed colon cancer before age 40 than in those diagnosed after age 70.The patterns of mutations are thought to arise when children are exposed to colibactin before age 10, researchers reported in Nature.The mutation patterns were particularly prevalent in countries with a high incidence of early-onset cases.'If someone acquires one of these... mutations by the time they're 10 years old, they could be decades ahead of schedule for developing colorectal cancer, getting it at age 40 instead of 60,' study leader Ludmil Alexandrov of UC San Diego said in a statement.advertisement'Not every environmental factor or behavior we study leaves a mark on our genome,' said Alexandrov. 'But we've found that colibactin is one of those that can. In this case, its genetic imprint appears to be strongly associated with colorectal cancers in young adults.'The researchers have found other mutational signatures in colorectal cancers from specific countries, particularly Argentina, Brazil, Colombia, Russia and Thailand.This suggests that local environmental exposures may also contribute to cancer risk, they said.'It's possible that different countries have different unknown causes,' study co-author Marcos Diaz-Gay of the Spanish National Cancer Research Center in Madrid said in a statement.'That could open up the potential for targeted, region-specific prevention strategies.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
4 days ago
- The Hindu
Using bacteriophages to combat antimicrobial resistance
If one has a urinary tract infection, for instance, the pathology lab will identify the bacterium to be, say, Escherichia coli. It will also determine the pathogen's sensitivity to over a dozen antibiotics. It is fine if the bacterium is sensitive to many or all of the drugs. The nightmare scenario is when it is resistant to all of them. Increasingly, antibiotics don't work because the bacteria have developed resistance. It is estimated that globally about five million people are dying of conditions related to antimicrobial resistance (AMR) each year. This may double by 2050. It is a silent pandemic. What is the solution? Largely, pharmaceutical companies have lost interest in developing new antibiotics. Whereas a drug for cancer is used for a long time, antibiotics are given for just a few days. Also, due to the problem of AMR, new antibiotics are used as sparingly as possible to prevent the development of resistance. Therefore there is no financial incentive for companies to work on new antibiotics. There is some drug development happening but probably not enough to address the AMR problem. Bacteriophages are 'good viruses' that naturally prey on bacteria. They are all around us, in the water, in the soil, in our gut, on our skin, etc. There are believed to be 10-times as many phages as bacteria on the earth. Phages were beginning to be used against bacterial infections about a century ago, but antibiotics superseded them once they were discovered. Unlike an antibiotic, which may be able to kill many species of bacteria, phages may only kill a few strains of a particular bacterium. Therefore only countries in the Soviet bloc, cut off from the antibiotics, continued to use them. An institute in Tbilisi, Georgia, with over 100 years of experience, is famous for its phage expertise. Due to AMR, the rest of the world is now rediscovering phages and relevant research is ongoing in many countries. Phages have been used for burns, foot ulcers, gut infections, respiratory infections, urinary tract infections, etc. There are two main strategies that have been used. One, isolate the bacteria from the infected tissue, check which phage works against it in the lab, grow more of that phage and administer it to the patient. These phages may come from a phage bank of one's own or in very serious cases one may even ask phage banks elsewhere in the world for help. These are natural phages. Then there are genetically engineered phages, which have been modified in the lab to, say, expand the variety of bacteria they can kill. To the extent that phages are being used as drugs, they have a unique feature. Bacteria can evolve to be resistant to an antibiotic; likewise, bacteria can evolve to be resistant to a phage. The unique part is that the phages, too, can evolve to avoid the bacterial resistance. The drug is not a constant but an evolving entity. This is therefore a headache for the regulators, since no drug has ever been approved that evolves. Further, since phages are very specific to bacteria, one phage will not work against a large fraction of, say, foot ulcers, as happens with an antibiotic (until we have to consider AMR). So it is also challenging to conduct randomised controlled trials when the drug needed for each patient may be different. The world is desperate for new treatment modalities for AMR. Thus far, no government in the Western world has approved a phage as a drug. But they may allow patients to access phages in the form of 'compassionate use', 'emergency-use expanded access' or 'special access' routes. These are often approvals for single, named patients who are in desperate need. Yet another route, used in Belgium for instance, is the 'magistral route' where particular pharmacies can 'compound' a phage specifically for a particular patient. The regulatory headache may be solved if the following scenario, which Jean-Paul Pirnay and colleagues in Belgium are researching, works out. Create a device in which all of the following steps can be conducted: isolate the bacteria from an infection, sequence its genome, use AI to determine which phage genome is the most likely to work, create the phage from scratch in the device, and administer it to the patient on the spot. In such a scenario, the phage wouldn't be regulated as a drug. Instead, the device would be regulated. And the device would only contain routinely used molecules such as nucleotides and enzymes that would be used to assemble the phage. The scale of AMR is such that we need many large initiatives to try and tackle it. If a group of microbiologists is looking for a grand challenge that uses AI, surely the Pirnay route is one worth exploring? Gayatri Saberwal is a consultant at the Tata Institute for Genetics and Society.
The Hindu
6 days ago
- The Hindu
Coimbatore restaurants adapt to ban on mayonnaise made from raw eggs
Following Tamil Nadu government's ban on the use of mayonnaise made from raw eggs, food business operators (FBOs) in Coimbatore have adapted to the regulation. The one-year ban, in effect since April 8, 2025, is intended to prevent food-borne illnesses caused by microbial contamination. The Food Safety and Standards Authority of India (FSSAI) had cited risks associated with raw egg-based mayonnaise, which can be a breeding ground for pathogens such as Salmonella typhimurium, Salmonella enteritidis, Escherichia coli, and Listeria monocytogenes, especially when not stored at recommended temperatures (0–5°C). In a promising development, the ban appears to have had limited economic impact on eateries in Coimbatore due to the availability of alternatives and increasing public awareness. Many restaurant owners report that customers are more conscious about food safety and are willing to accept minor taste differences or price increases if safety is ensured. According to Ramesh Babu, General Manager of restaurant chain Cockraco in the city, the switch had been made well in advance as it moved to eggless mayonnaise over three years ago. 'We procure in bulk from trusted manufacturers. Any hotelier's concern must be to provide good quality and hygienic food. If the mayonnaise costs a bit more, the food item can cost a bit more too - a shawarma that was ₹ 100 can be sold at ₹ 120. Customers are willing to pay for safety', he said. He also noted a behavioural shift among consumers. 'Earlier, customers would request multiple servings of mayonnaise. That demand has reduced significantly', he said. Shruthi S., who runs Momolicious in the city, said her team uses boiled egg whites as a viable substitute. 'Customers initially noticed the difference in taste, but have adjusted. The business has not been affected economically. We have simply explored what we can do differently to ensure that quality and safety go hand in hand', she said. Customers in the city have also welcomed the change. K. Sneha, 22, from Pappanaickenpalayam said she could not find much difference in the taste of mayonnaise after the ban. T. Anuradha, FSSAI Designated Officer for Coimbatore, said various steps are being taken to raise awareness on the ban in the city. 'Awareness meetings were held with fast food sellers on Wednesday. Queries of the restaurant owners regarding the mayonnaise ban were resolved, with alternatives being suggested. They received training on essential safety measures, food storage practices and pest control, and were also informed that the FSSAI would take strict action against eateries not complying with the same', said Dr. Anuradha, adding that FBOs have been extremely cooperative towards the change.
The Hindu
7 days ago
- The Hindu
Nanoplastics can make E. coli infections worse: study
Nanoplastics are bad news even though each one is only as small as a smoke particle. Research has shown that micro- and nano-plastics are present at the top of the tallest mountains, at the bottom of the deepest trenches, and even in our bloodstream, tissues, and in newborns as well. Their build-up has many toxic effects, including damage to cells and the genetic material inside. Now, a new study from researchers at the University of Illinois, Urbana-Champaign, has revealed that nanoplastics aren't just risky on their own: they also increase the risk from pathogens. The researchers found that nanoplastics with positively charged surfaces could make Escherichia coli, a foodborne pathogen, more virulent. The findings were published in the Journal of Nanobiotechnology. How bacteria work E. coli bacteria have a negative charge on their outer membranes. This can attract positively charged nanoplastics and increase the stress on the bacterium, making it produce more Shiga-like toxins. These are the proteins E. coli secrete and which cause disease. In older studies, scientists have looked at the impact of charged surfaces on non-pathogenic bacteria. The new study examined how charged surfaces affected a particular strain of E. coli. Similarly, while previous studies focused primarily on free-floating cells, the new one studied both free-floating cells and biofilms — a community of bacteria sticking to each other over a surface. Biofilms are hotspots where bacteria exchange genetic material with their neighbours. The research process The team members used a pathogenic E. coli strain that was resistant to the antibiotic rifampicin. They cultured the strain on agar plates and a nutrient-rich liquid medium called LB broth. Then they exposed the bacteria to polystyrene-based nanoplastics with three kinds of charges: positive, negative, and neutral. The team also cultured a second set of E. coli cells in LB broth for use as a control. This group wasn't exposed to nanoparticles. Finally, the researchers observed the growth of the free-floating cells and the biofilm at seven- and 15-day intervals, and used different tests to quantify the growth. For the study's purposes, the researchers used an environmental scanning electron microscope (ESEM) to track interactions between nanoparticles and free-floating cells. Unlike microscopy techniques that require samples to be prepared in protracted processes, ESEM can image 'wet' samples without too much preparation. It also operates in a low-vacuum or controlled gas atmosphere that prevents natural fibres and cellulose from becoming charged. The scientists conducted two tests to measure the concentration of carbohydrates and proteins in the biofilm. They performed a catalase assay to determine the cells' response to oxidative stress. E. coli produce the catalase enzyme to protect themselves against oxidative stress. Higher stress would mean more catalase activity. The team also extracted RNA from the bacteria for study, because gene transfers take place across biofilms. Changes in RNA may indicate such transfers have happened. What the study found The investigations revealed that nanoplastics with surface charges did add to the toxicity of bacterial cells. At first, charged nanoplastics kept cells from growing. But some cells eventually overcame the stress and began to grow. The development and viability of cells exposed to charged nanoplastics were different from those of cells that weren't. Changes in the bacterial RNA suggested genes were changing to ensure the E. coli survived better and became more able to cause disease. The study said both positively and negatively charged nanoplastics caused these changes. Beena D.B., assistant professor of biology at Azim Premji University's School of Arts and Sciences, has conducted preliminary work on the effect of microplastics on soil microbes and said her team had observed similar results. She cautioned that microplastic-induced biofilms are a significant health hazard and that increasing horizontal gene transfer between microbes raised the risk of them developing antibiotic resistance. It also causes excessive production of proteins that contribute to more severe disease, she added. (Manaswini Vijayakumar is interning with The Hindu.)
